Evolus partners with IBSA to license, distribute Profhilo in US
Share
Listen to the news
Evolus partners with IBSA to license, distribute Profhilo in US
  • Evolus entered an exclusive licensing and distribution deal with Switzerland’s IBSA to develop and commercialize Profhilo in the US.
  • Profhilo is a hyaluronic acid injectable positioned for skin quality; more than 4,800,000 treatments have been administered globally since 2015.
  • Evolus will run US development for regulatory approval, then lead commercialization using its existing sales and digital infrastructure.
  • Deal includes no upfront payments; economics use a transfer-price model targeting gross margins consistent with Evolus’ long-term framework.
  • Evolus expects no change to its 2026 outlook or its previously stated 2028 revenue and profitability targets.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evolus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260708437892) on July 08, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending